Viking Therapeutics (VKTX) Non Operating Income (2014 - 2026)

Viking Therapeutics has disclosed Non Operating Income across 13 years of filings, most recently posting $5.8 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $5.8 million, down 41.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.7 million (down 32.71% YoY), and the FY2025 annual result was $33.7 million, down 17.71% from the prior year.
• Non Operating Income came in at $5.8 million for Q1 2026 at Viking Therapeutics, down from $7.1 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $11.8 million in Q2 2024 to a low of $142000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $5.8 million (2026), against an average of $5.7 million.
• Across the five-year window, Non Operating Income surged 2168.84% in 2023 and plunged 41.06% in 2026, its largest moves.
• Viking Therapeutics' Non Operating Income stood at $724000.0 in 2022, then surged by 546.41% to $4.7 million in 2023, then soared by 131.22% to $10.8 million in 2024, then tumbled by 34.61% to $7.1 million in 2025, then dropped by 18.03% to $5.8 million in 2026.
• The last three Non Operating Income figures came in at $5.8 million (Q1 2026), $7.1 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.